114 related articles for article (PubMed ID: 19010920)
1. Melanoma-specific memory T cells are functionally active in Ret transgenic mice without macroscopic tumors.
Umansky V; Abschuetz O; Osen W; Ramacher M; Zhao F; Kato M; Schadendorf D
Cancer Res; 2008 Nov; 68(22):9451-8. PubMed ID: 19010920
[TBL] [Abstract][Full Text] [Related]
2. Effect of artesunate on immune cells in ret-transgenic mouse melanoma model.
Ramacher M; Umansky V; Efferth T
Anticancer Drugs; 2009 Nov; 20(10):910-7. PubMed ID: 19745721
[TBL] [Abstract][Full Text] [Related]
3. Tumor-reactive CD8+ early effector T cells identified at tumor site in primary and metastatic melanoma.
Anichini A; Molla A; Vegetti C; Bersani I; Zappasodi R; Arienti F; Ravagnani F; Maurichi A; Patuzzo R; Santinami M; Pircher H; Di Nicola M; Mortarini R
Cancer Res; 2010 Nov; 70(21):8378-87. PubMed ID: 20861189
[TBL] [Abstract][Full Text] [Related]
4. Melanoma-infiltrating dendritic cells induce protective antitumor responses mediated by T cells.
Preynat-Seauve O; Contassot E; Schuler P; French LE; Huard B
Melanoma Res; 2007 Jun; 17(3):169-76. PubMed ID: 17505262
[TBL] [Abstract][Full Text] [Related]
5. Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow.
Feuerer M; Beckhove P; Bai L; Solomayer EF; Bastert G; Diel IJ; Pedain C; Oberniedermayr M; Schirrmacher V; Umansky V
Nat Med; 2001 Apr; 7(4):452-8. PubMed ID: 11283672
[TBL] [Abstract][Full Text] [Related]
6. Skin melanoma development in ret transgenic mice despite the depletion of CD25+Foxp3+ regulatory T cells in lymphoid organs.
Kimpfler S; Sevko A; Ring S; Falk C; Osen W; Frank K; Kato M; Mahnke K; Schadendorf D; Umansky V
J Immunol; 2009 Nov; 183(10):6330-7. PubMed ID: 19841169
[TBL] [Abstract][Full Text] [Related]
7. Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients.
Speiser DE; Schwarz K; Baumgaertner P; Manolova V; Devevre E; Sterry W; Walden P; Zippelius A; Conzett KB; Senti G; Voelter V; Cerottini JP; Guggisberg D; Willers J; Geldhof C; Romero P; Kündig T; Knuth A; Dummer R; Trefzer U; Bachmann MF
J Immunother; 2010 Oct; 33(8):848-58. PubMed ID: 20842051
[TBL] [Abstract][Full Text] [Related]
8. [Ad hTRP2 - mediated immunity against melanoma is enhanced by dendritic cells pulsed with peptide].
Tan XH; Liu C; Wan YH
Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):658-61. PubMed ID: 17274369
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the class I-restricted gp100 melanoma peptide-stimulated primary immune response in tumor-free vaccine-draining lymph nodes and peripheral blood.
Walker EB; Miller W; Haley D; Floyd K; Curti B; Urba WJ
Clin Cancer Res; 2009 Apr; 15(7):2541-51. PubMed ID: 19318471
[TBL] [Abstract][Full Text] [Related]
10. Augmentation of antitumor immune responses after adoptive transfer of bone marrow derived from donors immunized with tumor lysate-pulsed dendritic cells.
Asavaroengchai W; Kotera Y; Koike N; Pilon-Thomas S; Mulé JJ
Biol Blood Marrow Transplant; 2004 Aug; 10(8):524-33. PubMed ID: 15282530
[TBL] [Abstract][Full Text] [Related]
11. Ret transgenic mouse model of spontaneous skin melanoma: focus on regulatory T cells.
Umansky V; Sevko A
Pigment Cell Melanoma Res; 2013 Jul; 26(4):457-63. PubMed ID: 23560814
[TBL] [Abstract][Full Text] [Related]
12. Dormant tumor cells interact with memory CD8
Flores-Guzmán F; Utikal J; Umansky V
Cancer Lett; 2020 Apr; 474():74-81. PubMed ID: 31962142
[TBL] [Abstract][Full Text] [Related]
13. Loss of CTL function among high-avidity tumor-specific CD8+ T cells following tumor infiltration.
Janicki CN; Jenkinson SR; Williams NA; Morgan DJ
Cancer Res; 2008 Apr; 68(8):2993-3000. PubMed ID: 18413769
[TBL] [Abstract][Full Text] [Related]
14. Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo.
Prévost-Blondel A; Zimmermann C; Stemmer C; Kulmburg P; Rosenthal FM; Pircher H
J Immunol; 1998 Sep; 161(5):2187-94. PubMed ID: 9725210
[TBL] [Abstract][Full Text] [Related]
15. Central role of tumor-associated CD8+ T effector/memory cells in restoring systemic antitumor immunity.
Kilinc MO; Gu T; Harden JL; Virtuoso LP; Egilmez NK
J Immunol; 2009 Apr; 182(7):4217-25. PubMed ID: 19299720
[TBL] [Abstract][Full Text] [Related]
16. Marked anti-tumor effects of CD8(+)CD62L(+) T cells from melanoma-bearing mice.
Liao Y; Geng P; Tian Y; Miao H; Liang H; Zeng R; Ni B; Ruan Z
Immunol Invest; 2015; 44(2):147-63. PubMed ID: 25122543
[TBL] [Abstract][Full Text] [Related]
17. Specific epitope-induced conversion of CD8+ memory cells into effector cytotoxic T lymphocytes in vitro: presentation of peptide antigen by CD8+ T cells.
Kos FJ; Müllbacher A
Eur J Immunol; 1992 Jun; 22(6):1595-601. PubMed ID: 1376266
[TBL] [Abstract][Full Text] [Related]
18. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma.
Mortarini R; Piris A; Maurichi A; Molla A; Bersani I; Bono A; Bartoli C; Santinami M; Lombardo C; Ravagnani F; Cascinelli N; Parmiani G; Anichini A
Cancer Res; 2003 May; 63(10):2535-45. PubMed ID: 12750277
[TBL] [Abstract][Full Text] [Related]
19. LFA-1 defect-induced effector/memory CD8+ T cell apoptosis is mediated via Bcl-2/Caspase pathways and associated with downregulation of CD27 and IL-15R.
Ye Z; Shi M; Xu S; Xiang J
Mol Immunol; 2010 Aug; 47(14):2411-21. PubMed ID: 20569988
[TBL] [Abstract][Full Text] [Related]
20. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]